% | $
Quotes you view appear here for quick access.

Athersys, Inc. Message Board

  • biojax biojax Oct 2, 2013 10:20 AM Flag

    ATHX is undervalued compared to OSIR and today


    Piper upgrades Osiris on Grafix optimism • 9:32 AM
    Piper's Edward Tenthoff is out with an upbeat note on Osiris Therapeutics (OSIR +4.5%), saying the presentation of full Diabetic Foot Ulcer data (expected in November) "will facilitate Grafix's reimbursement, contributing to significant biosurgery sales growth in 2014 and beyond."
    OSIR upgraded to Overweight from Neutral.
    Price target reiterated at $21.

    This topic is deleted.
2.02+0.02(+1.00%)Sep 23 4:00 PMEDT